Cancer Home > Aldesleukin
Clinical Effects of AldesleukinAldesleukin has been studied in people with metastatic kidney cancer and those with metastatic skin cancer. In the studies involving kidney cancer, 7 percent of people given aldesleukin had no evidence of cancer after treatment and 8 percent had at least a partial response to treatment. The response lasted from 3 to over 131 months.
When and How to Receive This MedicationSome general considerations to keep in mind during treatment with aldesleukin include the following:
- This medication is given as a slow injection into a vein (an intravenous, or IV, infusion), every eight hours for five days, followed by a nine-day break, and then an additional five days of treatment.
- The injection is normally administered by a healthcare provider in a healthcare setting, such as a hospital.
- It takes 15 minutes to complete each aldesleukin IV infusion.
- Your healthcare provider may give you other medicines to help prevent or manage certain side effects.
- Aldesleukin should be inspected before use, and should not be given if it contains particles or is discolored.
- For the medication to work properly, it must be used as prescribed.